プロテアソーム阻害薬のパイプライン分析

【英語タイトル】Proteasome Inhibitors Therapeutics Pipeline, 2017 - Clinical Trials & Results, Patents, Designations, Collaborations, and Other Developments

P&S Market Researchが出版した調査資料(PSM802141)・商品コード:PSM802141
・発行会社(調査会社):P&S Market Research
・発行日:2017年10月1日
・ページ数:89
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD5,000 ⇒換算¥565,000見積依頼/購入/質問フォーム
Group License(5名様閲覧用)USD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD1,850 ⇒換算¥209,050見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

The study analyzed that the proteasome inhibitor therapeutics pipeline comprises approximately 20 drug candidates in different stages of development. Protein degradation and synthesis in the body are regulated by proteasome activity of multimeric protease complex. The protein conjugated to multiple units of polypeptide proteasome ubiquitin are degraded by proteasome. The accumulation of ubiquitinated proteins can lead to apoptosis. The proteasome units include 20S core catalytic complex and 19S regulatory subunits at each end, forming 26S complex. Ubiquitin is 76 amino acids complex and covalently linked to proteins by an enzymatic reaction.
Insights on pipeline segments

According to the research findings, most of the drug candidates of the proteasome inhibitor therapeutics are being developed as the small molecules.

Advancements in Technologies Driving the Growth of Proteasome Inhibitor Therapeutics Candidates

Majority of companies in the pipeline have innovated various advanced technologies for developing drug candidates as proteasome inhibitors. For instance, Ensemble Therapeutics’, Corporation technology platform is an efficient and productive approach for developing synthetic macrocycles and other less conventional small molecules. While macrocycles are a class of compounds that have traditionally been obtained from natural sources, the company is synthesizing successfully the synthetic macrocycles possessing drug-like properties and features. Using this approach, the company has developed a pipeline of proprietary and partnered programs that focus on both extracellular proteins (e.g. IL-17) and challenging intracellular targets (e.g. IAPs, IDO and USP9x).

Various Collaborations for Proteasome Inhibitor Therapeutics Development

Viteava Pharmaceuticals Inc. (Viteava) announced the execution of a sponsored research agreement with McGill University relating to novel analogs and derivatives of the green tea flavonoid, (-) epigallocatechin-3-gallate (EGCG).

Some of the key players developing drugs as proteasome inhibitors include Triphase Accelerator Corporation, Cantex Pharmaceuticals, Inc., Accuitis, Inc. and others.

【レポートの目次】

Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1 Overview

4.2 Key Drivers

4.3 Key Barriers

4.4 Proteasome Inhibitor Pipeline Analysis

4.4.1 Pipeline Analysis by Phase

4.4.2 Pipeline Analysis by Molecule Type

4.4.3 Pipeline Analysis by Route of Administration

4.4.4 Pipeline Analysis by Company

Chapter 5. Proteasome Inhibitor Therapeutics Pipeline Analysis by Phase (2017)

5.1 Phase II: Drug profiles

5.1.1 Pre-Clinical Study

5.1.2 Pre-Clinical Results

5.1.3 Clinical Trials

5.1.4 Clinical Results

5.1.5 Strategic Development

5.1.6 Designation

5.1.7 Grants

5.1.8 Patent

5.1.9 Technology

5.2 Phase I: Drug profiles

5.2.1 Pre-Clinical Study

5.2.2 Pre-Clinical Results

5.2.3 Clinical Trials

5.2.4 Clinical Results

5.2.5 Strategic Development

5.2.6 Designation

5.2.7 Grants

5.2.8 Patent

5.2.9 Technology

5.3 Pre-Clinical: Drug profiles

5.3.1 Pre-Clinical Study

5.3.2 Pre-Clinical Results

5.3.3 Strategic Development

5.3.4 Designation

5.3.5 Grants

5.3.6 Patent

5.3.7 Technology

5.4 Discovery: Drug profiles

5.4.1 Strategic Development

5.4.2 Designation

5.4.3 Grants

5.4.4 Patent

5.4.5 Technology

Chapter 6. Clinical Trials Analysis

6.1 Clinical Trials, by Region

6.2 Clinical Trials, by Trial Status

Chapter 7. Competitive Landscape

7.1 Key Players Benchmarking for Proteasome Inhibitor Therapeutics Pipeline

7.2 SWOT Analysis of Proteasome Inhibitor Therapeutics Pipeline

7.2.1 Strengths

7.2.2 Weaknesses

7.2.3 Opportunities

7.2.4 Threats

Chapter 8. Company Profiles

8.1 Business Overview

8.2 Product and Service Offerings

Chapter 9. Appendix

9.1 Abbreviations

9.2 Related Reports

LIST OF TABLES

PIPELINE ANALYSIS OF PROTEASOME INHIBITOR BY COMPANY (2017)

DESCRIPTION OF PHASE II DRUG CANDIDATES

CLINICAL TRIALS OF PHASE II DRUG CANDIDATES

DESCRIPTION OF PHASE I DRUG CANDIDATES

CLINICAL TRIALS OF PHASE I DRUG CANDIDATES

DESCRIPTION OF PRE-CLINICAL DRUG CANDIDATES

DESCRIPTION OF DISCOVERY DRUG CANDIDATES

COMPANIES – AT A GLANCE

LIST OF FIGURES

RESEARCH METHODOLOGY

SPLIT OF PRIMARY AND SECONDARY RESEARCH

BREAKDOWN OF PRIMARY RESEARCH BY INDUSTRY PARTICIPANT

BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE

NUMBER OF PROTEASOME INHIBITOR DRUG CANDIDATES UNDER DEVELOPMENT (2017)

PROTEASOME INHIBITOR PIPELINE SPLIT, BY MOLECULE TYPE (2017)

PROTEASOME INHIBITOR PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2017)

BREAKDOWN OF CLINICAL TRIALS, BY REGION

BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS

KEY PLAYERS BENCHMARKING

SWOT ANALYSIS



【レポートのキーワード】

プロテアソーム阻害薬

★調査レポート[プロテアソーム阻害薬のパイプライン分析] (コード:PSM802141)販売に関する免責事項を必ずご確認ください。
★調査レポート[プロテアソーム阻害薬のパイプライン分析]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆